My Clinic is in the United States
My Clinic is in Canada
Find out how we are Changing Fertility Care For Generations To Come at the 77th ASRM 2021 Scientific Congress & Expo at The Baltimore Convention Center.
This year, you can get a sneak preview of our latest genetic tests. To find out more, we invite you to book a meeting today with our genomics experts.
At our booth, 2407, you can also discover more about our PGTaiSM 2.0 Plus platform, and how we are advancing reproductive genomic testing to improve the chances of successful implantation with the ERPeakSM endometrial receptivity test.
We also have an exciting education program lined up. Read on to find out more!
Symposia featuring our genomics experts
Look out for our speakers on the ASRM 2021 Scientific Program at their CME accredited talks.
At our booth
Come and talk to us about our PGTai 2.0 Plus platform which includes all the core benefits of our standard PGT-A offering plus parental QC assessment, parent of origin of aneuploidy assessment, and genetic PN checking.
You can also find out how we are advancing reproductive genomic testing to improve the chances of successful implantation with the ERPeakSM endometrial receptivity test.
Don’t Miss Our Poster Presentations at the Congress
Retrospective analysis of 479 PGTSR cycles – analysis of chromosome information and availability of embryos for transfer
This poster breaks down CooperSurgical’s observed PGT-SR results for different types of chromosomal rearrangements. Results are useful for PGT-SR patient counseling.
Usable embryos post PGT-M for ataxiatelangiectasia- mutated gene: recessive vs. dominant
The ATM gene confers both an autosomal dominant risk for breast cancer and an autosomal recessive risk for Ataxia-Telangiectasia. What are the testing outcomes for families pursuing PGT-M for autosomal dominant vs recessive disease?
Reporting embryo mosaicism using preimplantation genetic testing for aneuploidy (PGT-A): impact on euploidy rate and likelihood of embryos available for transfer
This poster compares the PGT-A outcomes of cycles that report vs. mask mosaicism. How does reporting or masking mosaicism affect the number of embryos available for transfer? That may depend on clinics’ individual transfer policies.
Examination of inter centre variation in PGT-A “no result rate” and efficacy of rebiopsy – analysis of 22,833 samples 2015-2019
Five years of PGT-A lab experience indicate that, while few embryos are transferred following an initial no result, the embryos that are rebiopsied have better clinical outcomes than those that are transferred untested.
Inter-cycle consistency of the window of implantation (woi) in a sub-fertile patient population
Results of ERPeak testing on sequential endometrial biopsies indicate that the window of implantation tends to be consistent across a patient’s menstrual cycles.
PGT-M for autosomal recessive carriers of conditions with an autosomal dominant cancer risk: a call for action
Pathogenic variants in several genes are associated with both severe autosomal recessive disease and variable autosomal dominant cancer risk. This poster assesses rates of PGT-M for genes displaying this duality, and underscores the importance of thorough patient counseling in such situations.
PGT-M to prevent 2 or 3 genetic disorders, mostly dominant
CooperSurgical’s experience testing embryos for multiple single-gene disorders at once suggests that patients requiring multi-gene PGT-M should prepare to complete multiple IVF cycles to achieve a healthy liveborn child.
